JonesTrading Has Lowered Expectations for ArriVent BioPharma (NASDAQ:AVBP) Stock Price

ArriVent BioPharma (NASDAQ:AVBP) had its target price lowered by analysts at JonesTrading from $45.00 to $22.00 in a research report issued on Wednesday, Benzinga reports. The brokerage currently has a “buy” rating on the stock. JonesTrading’s price objective would suggest a potential upside of 28.46% from the stock’s previous close.

Several other analysts have also commented on AVBP. Weiss Ratings reissued a “sell (d-)” rating on shares of ArriVent BioPharma in a report on Friday, July 17th. HC Wainwright increased their target price on ArriVent BioPharma from $44.00 to $47.00 and gave the company a “buy” rating in a research report on Monday, August 17th. Cantor Fitzgerald reissued an “overweight” rating on shares of ArriVent BioPharma in a report on Tuesday, September 22nd. Guggenheim reduced their price objective on shares of ArriVent BioPharma from $45.00 to $18.00 and set a “buy” rating for the company in a research report on Wednesday. Finally, Jefferies Financial Group set a $18.00 price objective on shares of ArriVent BioPharma in a report on Tuesday. Nine equities research analysts have rated the stock with a Buy rating, one has issued a Hold rating and one has assigned a Sell rating to the stock. Based on data from MarketBeat, ArriVent BioPharma currently has an average rating of “Moderate Buy” and a consensus price target of $31.89.

ArriVent BioPharma Stock Up 13.5%

Shares of AVBP stock traded up $2.04 during mid-day trading on Wednesday, hitting $17.13. 2,644,426 shares of the stock were exchanged, compared to its average volume of 636,434. The firm has a fifty day moving average of $29.57 and a 200 day moving average of $29.43. ArriVent BioPharma has a 52-week low of $11.36 and a 52-week high of $35.83. The company has a market cap of $844.45 million, a PE ratio of -4.71 and a beta of 1.34.

ArriVent BioPharma (NASDAQ:AVBP) last posted its earnings results on Wednesday, August 12th. The company reported ($1.05) EPS for the quarter, missing analysts’ consensus estimates of ($0.99) by ($0.06). Equities analysts predict that ArriVent BioPharma will post -4.11 EPS for the current year.

Hedge Funds Weigh In On ArriVent BioPharma

Hedge funds and other institutional investors have recently modified their holdings of the business. Tema ETFs LLC purchased a new stake in shares of ArriVent BioPharma in the second quarter valued at approximately $1,981,000. Deutsche Bank AG purchased a new position in ArriVent BioPharma during the second quarter worth approximately $1,361,000. Dimensional Fund Advisors LP lifted its position in ArriVent BioPharma by 758.2% during the first quarter. Dimensional Fund Advisors LP now owns 126,525 shares of the company’s stock worth $2,918,000 after buying an additional 111,782 shares in the last quarter. E Fund Management Co. Ltd. acquired a new position in ArriVent BioPharma during the second quarter worth $3,798,000. Finally, Bank of America Corp DE grew its holdings in ArriVent BioPharma by 41.9% in the 1st quarter. Bank of America Corp DE now owns 80,208 shares of the company’s stock valued at $1,850,000 after buying an additional 23,687 shares in the last quarter. 9.48% of the stock is owned by hedge funds and other institutional investors.

Key ArriVent BioPharma News

Here are the key news stories impacting ArriVent BioPharma this week:

• Neutral Sentiment: Trading in AVBP was temporarily halted pending news before the company released its clinical-trial update, reflecting the expected market sensitivity of the announcement.
• Negative Sentiment: ArriVent reported that the Phase 3 FURVENT trial of firmonertinib in previously untreated patients with EGFR exon 20 insertion-mutated non-small cell lung cancer failed to meet its primary endpoint of progression-free survival, as assessed by blinded independent central review. ArriVent FURVENT Phase 3 program update
• Negative Sentiment: The trial failure affects ArriVent’s lead asset and significantly weakens the near-term investment case. Analysts and industry coverage characterized the outcome as a late-stage setback, with the company reviewing its future plans for firmonertinib. ArriVent reviews firmonertinib plans
• Negative Sentiment: Reports described a roughly 58%–60% collapse in the stock following the failed primary endpoint, while the shares approached a new one-year low. The reaction reflects reduced expectations for firmonertinib’s approval and commercial potential. ArriVent shares plunge on FURVENT failure
• Negative Sentiment: Levi & Korsinsky announced a potential investor investigation after the trial failure. The notice highlighted shareholder losses and noted that ArriVent had launched a $250 million at-the-market stock offering approximately five months earlier, adding potential litigation and dilution concerns. ArriVent investor investigation notice

About ArriVent BioPharma

ArriVent BioPharma, Inc is a clinical-stage biopharmaceutical company focused on developing and commercializing precision medicines for patients with genetically defined cancers. The company seeks to identify promising therapies developed in other regions and advance them through clinical development and regulatory approval in the United States and other markets.

ArriVent’s lead product candidate is furmonertinib, an oral, irreversible epidermal growth factor receptor (EGFR) tyrosine kinase inhibitor designed to target specific EGFR mutations in non-small cell lung cancer, including EGFR exon 20 insertion mutations.